Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors ...Middle East

MORRISVILLE, NC., July 8, 2024 /PRNewswire/ -- Immorna Biotherapeutics, Inc. (Immorna), a clinical stage biotechnology company developing both self-replicating and conventional mRNA-based therapeutics and vaccines, announced today that the U.S. Food and Drug Administration (FDA) has...

Hence then, the article about immorna biotherapeutics receives u s fda ind clearance to conduct phase 1 2 study of jcxh 211 iv as monotherapy and in combination with checkpoint inhibitor in patients with advanced solid tumors was published today ( Monday 08/07/2024 - 11:33 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Immorna Biotherapeutics Receives U.S. FDA IND Clearance to Conduct Phase 1/2 Study of JCXH-211 IV as Monotherapy and in Combination with Checkpoint Inhibitor in Patients with Advanced Solid Tumors )

Also on site :

• Box Office Smash That ‘Saved Cinema’ Is Now Streaming Free for the First Time Ever
• Politics latest: Reeves to cut food costs and offer free children’s bus rides in cost of living package
• Chelsea Handler Slams ‘Bigots’ Shane Gillis and Tony Hinchcliffe for ‘Racist’ Roast Jokes: ‘I Wasn’t Fine With That’